Leishmania panamensis infection and antimonial drugs modulate expression of macrophage drug transporters and metabolizing enzymes: Impact on intracellular parasite survival

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 1, 2014, Pages 139-149

  Gómez, Maria Adelaida ^a   Navas, Adriana ^a   Márquez, Ricardo ^a   Rojas, Laura Jimena ^a   Vargas, Deninson Alejandro ^a   Blanco, Victor Manuel ^a   Koren, Roni ^b   Zilberstein, Dan ^b   Saravia, Nancy Gore ^a  

^a CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

ABCB6; Host pathogen interactions; Leishmaniasis; MT2A; Phagolysosomes

Indexed keywords

ABCB6 PROTEIN; ALOX5 PROTEIN; AQUAPORIN 1; AQUAPORIN 9; CALGRANULIN B; CARRIER PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE TRANSFERASE M3; MEGLUMINE ANTIMONATE; METALLOTHIONEIN II; MGST2 PROTEIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; SHORT HAIRPIN RNA; SLC5A4 PROTEIN; SLC7A11 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HOST CELL; HUMAN; LEISHMANIA PANAMENSIS; LEISHMANIA PANAMENSIS INFECTION; MACROPHAGE; MALE; MONOCYTE; NONHUMAN; PARASITE SURVIVAL; PHAGOLYSOSOME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN LEISHMANIASIS; TREATMENT FAILURE; TREATMENT RESPONSE;

ABCB6; HOST-PATHOGEN INTERACTIONS; LEISHMANIASIS; MT2A; PHAGOLYSOSOMES;

ADULT; ANTIPROTOZOAL AGENTS; CELL SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HOST-PATHOGEN INTERACTIONS; HUMANS; LEISHMANIA; MACROPHAGES; MALE; MEGLUMINE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; YOUNG ADULT;

EID: 84890399789     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt334     Document Type: Article

References (38)

1. Murray HW, Delph-Etienne S. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun 2000; 68: 288-93.
2. Murray HW, Jungbluth A, Ritter E et al. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect Immun 2000; 68: 6289-93.
3. MurrayHW, Montelibano C, Peterson R et al. Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J Infect Dis 2000; 182: 1497-502.
4. Bacellar O, Lessa H, SchrieferAet al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 2002; 70: 6734-40.
5. Diaz YR, Rojas R, Valderrama L et al. T-bet, GATA-3, and Foxp3 expression andTh1/Th2cytokine production in the clinicaloutcomeofhumaninfection with Leishmania (Viannia) species. J Infect Dis 2010; 202: 406-15.
6. Alvar J, Aparicio P, Aseffa A et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21: 334-59.
7. Rojas R, Valderrama L, Valderrama M et al. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 2006; 193: 1375-83.
8. Robledo SM, Valencia AZ, Saravia NG. Sensitivity to Glucantime of Leishmania viannia isolated from patients prior to treatment. J Parasitol 1999; 85: 360-6.
9. Jackson JE, Tally JD, Ellis WYet al. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy. Am J Trop Med Hyg 1990; 43: 464-80.
10. Cruz A, Rainey PM, Herwaldt BL et al. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis 2007; 195: 602-8.
11. Mookerjee Basu J, Mookerjee A, Banerjee R et al. Inhibition of ABC transporters abolishes antimony resistance in Leishmania infection. Antimicrob Agents Chemother 2008; 52: 1080-93.
12. Fernandez O, Diaz-Toro Y, Valderrama L et al. Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp. J Clin Microbiol 2012; 50: 2207-11.
13. Roy G, Dumas C, Sereno D et al. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol Biochem Parasitol 2000; 110: 195-206.
14. Yu Z, Genest PA, ter Riet B et al. The protein that binds to DNA base J in trypanosomatids has features of a thymidine hydroxylase. Nucleic Acids Res 2007; 35: 2107-15.
15. Zhou H, DeLoid G, Browning E et al. Genome-wide RNAi screen in IFN-g-treated human macrophages identifies genes mediating resistance to the intracellular pathogen Francisella tularensis. PLoS One 2012; 7: e31752.
16. Moffat J, Grueneberg DA, Yang X et al. A lentiviral RNAi library for human andmousegenes applied to anarrayedviral high-content screen. Cell 2006; 124: 1283-98.
17. Krishnamurthy PC, Du G, Fukuda Y et al. Identification of a mammalian mitochondrial porphyrin transporter. Nature 2006; 443: 586-9.
18. Chavan H, Oruganti M, Krishnamurthy P. The ATP-binding cassette transporter ABCB6 is induced by arsenic and protects against arsenic cytotoxicity. Toxicol Sci 2011; 120: 519-28.
19. Paterson JK, Shukla S, Black CMet al. HumanABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane. Biochemistry 2007; 46: 9443-52.
20. Jalil YA, Ritz V, Jakimenko A et al. Vesicular localization of the rat ATP-binding cassette half-transporter rAbcb6. Am J Physiol Cell Physiol 2008; 294: C579-90.
21. Kiss K, Brozik A, Kucsma N et al. Shifting the paradigm: the putative mitochondrial protein ABCB6 resides in the lysosomes of cells and in the plasma membrane of erythrocytes. PLoS One 2012; 7: e37378.
22. Della Valle MC, Sleat DE, Zheng H et al. Classification of subcellular location by comparative proteomic analysis of native and density-shifted lysosomes. Mol Cell Proteomics 2011; 10: M110.006403.
23. Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol 2011; 9: 604-15.
24. Van Bambeke F, Glupczynski Y, Plesiat P et al. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J AntimicrobChemother 2003; 51: 1055-65.
25. Van Bambeke F, Michot JM, Tulkens PM. Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J Antimicrob Chemother 2003; 51: 1067-77.
26. FordJ, KhooSH, Back DJ. Theintracellularpharmacologyof antiretroviral protease inhibitors. J Antimicrob Chemother 2004; 54: 982-90.
27. Lemaire S, Kosowska-Shick K, Appelbaum PC et al. Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother 2010; 54: 2549-59.
28. Bhattacharjee H, Carbrey J, Rosen BP et al. Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. Biochem Biophys Res Commun 2004; 322: 836-41.
29. Sato H, Shiiya A, Kimata M et al. Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol Chem 2005; 280: 37423-9.
30. Mandal PK, Seiler A, Perisic Tet al. System xc 2 and thioredoxin reductase 1 cooperatively rescue glutathione deficiency. J Biol Chem 2010; 285: 22244-53.
31. Ferreira Cdos S, Martins PS, Demicheli C et al. Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione. Biometals 2003; 16: 441-6.
32. Albores A, Koropatnick J, Cherian MG et al. Arsenic induces and enhances rat hepatic metallothionein production in vivo. Chem Biol Interact 1992; 85: 127-40.
33. Sabolic I, Breljak D, Skarica M et al. Role of metallothionein in cadmium traffic and toxicity in kidneys and other mammalian organs. Biometals 23: 897-926.
34. Liu J, Liu Y, Habeebu SM et al. Chronic combined exposure to cadmium and arsenic exacerbates nephrotoxicity, particularly in metallothionein-I/II null mice. Toxicology 2000; 147: 157-66.
35. Liu J, Liu Y, Goyer RA et al. Metallothionein-I/II null mice are more sensitive than wild-type mice to the hepatotoxic and nephrotoxic effects of chronic oral or injected inorganic arsenicals. Toxicol Sci 2000; 55: 460-7.
36. Gregory DJ, Sladek R, Olivier M et al. Comparison of the effects of Leishmania major or Leishmania donovani infection on macrophage gene expression. Infect Immun 2008; 76: 1186-92.
37. El Fadili K, Imbeault M, Messier N et al. Modulation of gene expression in human macrophages treated with the anti-Leishmania pentavalent antimonial drug sodium stibogluconate. Antimicrob Agents Chemother 2008; 52: 526-33.
38. Chaussabel D, Semnani RT, McDowell MA et al. Unique gene expression profiles of human macrophages and dendritic cells to phylogenetically distinct parasites. Blood 2003; 102: 672-81.